Figures & data
Figure 1 Patient disposition.
Abbreviations: ASE, all subjects enrolled; TIO, tiotropium; UMEC, umeclidinium.
![Figure 1 Patient disposition.](/cms/asset/1c406930-7640-47dd-a57e-4b070edfaf3d/dcop_a_102494_f0001_b.jpg)
Table 1 Baseline demographics and clinical characteristics (ITT population)
Table 2 Summary of lung function end points (ITT and TFH populations)
Figure 2 LS mean change from baseline in trough FEV1 (mL) (PP population).
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; LS, least squares; PP, per-protocol; SE, standard error; TIO, tiotropium; UMEC, umeclidinium.
![Figure 2 LS mean change from baseline in trough FEV1 (mL) (PP population).](/cms/asset/003b4552-d11b-4604-b1a3-8d18486dfad6/dcop_a_102494_f0002_c.jpg)
Figure 3 LS mean change from baseline in serial FEV1 (mL) on day 1 (A) and on day 84 (B) (both days: TFH population).
![Figure 3 LS mean change from baseline in serial FEV1 (mL) on day 1 (A) and on day 84 (B) (both days: TFH population).](/cms/asset/4c88b1fb-0d9d-4047-ab88-50a81e64533c/dcop_a_102494_f0003_c.jpg)
Table 3 Summary of symptomatic and health-related quality of life end points (ITT population)
Table 4 Inhaler assessments
Figure 4 Proportion of trough FEV1 responders.
Abbreviations: CI, confidence interval; OR, odds ratio; FEV1, forced expiratory volume in 1 second; TIO, tiotropium; UMEC, umeclidinium.
![Figure 4 Proportion of trough FEV1 responders.](/cms/asset/046bee12-7f00-4da6-a4ed-9c6054eec664/dcop_a_102494_f0004_c.jpg)
Table 5 Summary of safety results (ITT population)